Back to top

biotechs: Archive

Sundeep Ganoria

How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High

BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.

BBIOPositive Net Change AZNNegative Net Change PFENegative Net Change

Zacks Equity Research

Immunome Stock Up 32% in a Month: Here's What You Should Know

IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.

IMNMNegative Net Change AMRNNegative Net Change PTCTNegative Net Change LQDAPositive Net Change

Zacks Equity Research

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

FBRXNegative Net Change NVAXNegative Net Change AMRNNegative Net Change LQDAPositive Net Change

Ahan Chakraborty

NVO Rallies 11% in a Month: How Should Investors Play the Stock?

Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.

NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change

Zacks Equity Research

United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know

UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.

UTHRNegative Net Change NBIXNegative Net Change AMRNNegative Net Change LQDAPositive Net Change

Debanjana Dey

BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?

bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.

BIAFNegative Net Change ADMANegative Net Change ALXOPositive Net Change

Ethan Feller

Stocks Look Shaky, But This Sector is Booming (Biotech)

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

LLYNegative Net Change ILMNPositive Net Change EXELNegative Net Change XLVNegative Net Change PTCTNegative Net Change XBIPositive Net Change FTREPositive Net Change

Zacks Equity Research

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

PRTANegative Net Change RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change

Zacks Equity Research

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.

TVRDNegative Net Change NVAXNegative Net Change AMRNNegative Net Change LQDAPositive Net Change

Zacks Equity Research

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

NTLAPositive Net Change BEAMPositive Net Change CRSPPositive Net Change